HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Immunotherapy Strategies Explored in HER2+ Breast Cancer

October 26th 2018

Although the first steps have been taken with immunotherapy in breast cancer, Sherene Loi, MBBS, FRACP, PhD, FAHMS, said development is still lagging in HER2-positive disease because of effective anti-HER2 therapies available.

Dr. Barrio on Treatment Options for HER2+ Breast Cancer

October 23rd 2018

Andrea V. Barrio, MD, FACS, breast surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with HER2-positive breast cancer.

Dr. Gradishar on Personalized Treatment in Breast Cancer

October 17th 2018

William J. Gradishar, MD, chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the rise of personalized treatment in breast cancer.

Adjuvant T-DM1 Improves iDFS in Phase III HER2+ Breast Cancer Trial

October 15th 2018

Ado-trastuzumab emtansine (T-DM1; Kadcyla) was found to significantly reduce the risk of disease recurrence or death compared with trastuzumab (Herceptin) as an adjuvant treatment in patients with HER2-positive early breast cancer who have residual disease following neoadjuvant therapy.

Expert Discusses Developments in HER2+ Breast Cancer

October 12th 2018

A. Jo Chien, MD, discusses emerging agents and other developments in HER2-positive breast cancer.

Dr. Hurvitz on Novel Agents in HER2-Positive Breast Cancer

October 10th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses novel agents in HER2-positive breast cancer.

Dr. Chien on Treatment Duration in HER2+ Breast Cancer

October 4th 2018

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment duration in HER2-positive breast cancer.

Dr. Formenti on Recent Progress With HER2-Targeted Therapy

October 2nd 2018

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the recent progress with HER2-targeted therapy in the treatment of breast cancer.

Regimen Could Reduce Cardiotoxicity in HER2+ Breast Cancer

September 28th 2018

Women with operable HER2-positive breast cancer had similar long-term survival outcomes with either concurrent or sequential chemotherapy in the neoadjuvant setting, according to newly published results from the phase III ACOSOG Z1041 trial.

Dr. Kalinsky on CNS Involvement in HER2+ Breast Cancer

September 20th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses central nervous system involvement in HER2-positive breast cancer.

Hurvitz Evaluates De-Escalation Strategies in Early-Stage HER2+ Breast Cancer

September 19th 2018

Sara A. Hurvitz, MD, discusses de-escalation strategies in early-stage HER2-positive breast cancer and novel HER2-targeted therapies in development.

Dr. Tolaney Reflects on Data from the PERSEPHONE Trial

September 18th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, reflects on data from the PERSEPHONE trial in HER2-positive breast cancer.

Dr. Hurvitz on HER2-Targeted Therapies in Breast Cancer

September 13th 2018

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses HER2-targeted therapies for the treatment of breast cancer.

Dr. Murthy on De-Escalation Strategies in HER2-Positive Breast Cancer

September 6th 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses de-escalation strategies for patients with HER2-positive breast cancer.

Dr. Kalinsky Discusses the Evolution of HER2+ Breast Cancer

September 5th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the evolution of treatment for patients with HER2-positive metastatic breast cancer.

Tolaney Discusses Developments Across Breast Cancer Subtypes

August 28th 2018

Sara M. Tolaney, MD, MPH, discusses developments in the treatment paradigms for patients with HR-positive or HER2-positive breast cancer.

Dr. Sparano Discusses Unmet Needs in Metastatic Breast Cancer

August 27th 2018

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses unmet needs in metastatic breast cancer.

Dr. Tolaney Discusses the Role of Chemotherapy in HER2+ Breast Cancer

August 22nd 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the role of chemotherapy in the treatment of patients with HER2-positive breast cancer.

New Recommendations Improve Accuracy of HER2 Status Designation

August 17th 2018

The guidelines for establishing HER2 status for patients with breast cancer with unclear results on initial testing have been finetuned in an update that the American Society of Clinical Oncology and the College of American Pathologists recently issued.

CNS Metastases Remain Unmet Need in HER2+ Breast Cancer

August 14th 2018

Kevin Kalinsky, MD, discusses the current treatment landscape of metastatic HER2-positive breast cancer, the potential for immunotherapy, and what is on the horizon for patients in this population who develop brain metastases.